These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 12741953

  • 1. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM.
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI.
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC, Pullen MA, Edwards RM, Louttit JB, West R, Brooks DP.
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [Abstract] [Full Text] [Related]

  • 4. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
    Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE.
    Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W, Dominiak P, Dendorfer A.
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
    Bäcklund T, Palojoki E, Grönholm T, Eriksson A, Vuolteenaho O, Laine M, Tikkanen I.
    Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
    [Abstract] [Full Text] [Related]

  • 7. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.
    Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM.
    J Hypertens; 2001 May; 19(5):941-6. PubMed ID: 11393678
    [Abstract] [Full Text] [Related]

  • 8. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C, Fortin D, Rouleau JL, Molinaro G, Adam A.
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [Abstract] [Full Text] [Related]

  • 9. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC.
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [Abstract] [Full Text] [Related]

  • 10. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
    Azizi M, Lamarre-Cliche M, Labatide-Alanore A, Bissery A, Guyene TT, Ménard J.
    J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
    [Abstract] [Full Text] [Related]

  • 11. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
    Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D.
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
    [Abstract] [Full Text] [Related]

  • 12. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
    [Abstract] [Full Text] [Related]

  • 13. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T, Cheruvu M, Olsufka R, Sandvik ER, Lane CE, Budman J, Hill CM, Klein U, Hegde SS.
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [Abstract] [Full Text] [Related]

  • 14. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA.
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [Abstract] [Full Text] [Related]

  • 15. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, Burrell LM, Cooper ME.
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
    Azizi M, Massien C, Michaud A, Corvol P.
    Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O, Reeves RA.
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.